Tessera
Jan 14, 2021
Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate
Gilead and Vir Biotechnology Establish Clinical Collaboration Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clinical collaboration to assess novel therapeutic combination strategies to develop a functional remedy for chronic hepatitis B virus (HBV). T...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
